Pathways to control the spreading of α-synuclein (α-syn) and associated neuropathology in Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) are unclear. Here, we show that preformed α-syn fibrils (PFF) increase the association between TLR2 and MyD88, resulting in microglial activation. The TLR2-interaction domain of MyD88 (wtTIDM) peptide-mediated selective inhibition of TLR2 reduces PFF-induced microglial inflammation in vitro. In PFF-seeded A53T mice, the nasal administration of the wtTIDM peptide, NEMO-binding domain (wtNBD) peptide, or genetic deletion of TLR2 reduces glial inflammation, decreases α-syn spreading, and protects dopaminergic neurons by inhibiting NF-κB. In summary, α-syn spreading depends on the TLR2/MyD88/NF-κB pathway and it can be reduced by nasal delivery of wtTIDM and wtNBD peptides.
Parkinson’s disease (PD) is the most prevalent movement disorder affecting almost 6.1 million people worldwide1. The disease is caused by a specific loss of tyrosine hydroxylase (TH) positive dopaminergic (DAergic) neurons present in substantia nigra pars compacta (SNpc). One of the pathologic hallmarks of PD is the presence of Lewy bodies (LBs) containing aggregated α-syn. Lowering the deposition of aggregated α-syn from the brain parenchyma is expected to reduce the development and progression of not only sporadic and familial PD, but also dementia with Lewy bodies (DLB) and multiple system atrophy (MSA)2,3,4.
It has been well manifested that point mutations (A53T, A30P, E46K, etc.) in the N-terminal region of α-syn or over-expression of the WT protein by gene duplication and triplication initiate amyloidogenesis5, resulting in the formation of oligomeric and protofibrillar form of α-syn. Usually, α-syn aggregates are released from the neurons by exocytosis and the extracellular α-syn can spread into glial cells or neighboring neurons by cell-to-cell transfer or by non-cell-autonomous manner6,7,8,9, inducing chronic inflammation in affected brain regions10,11. However, mechanisms by which α-syn spreading could be controlled are poorly understood. Activation of TLR2 requires its association with downstream adapter protein MyD8812,13. Recently, we have delineated that peptides corresponding to the TLR2-interacting domain of MyD88 (TIDM) specifically inhibit the induction of TLR2 activation without inhibiting either basal TLR2 activity or the activation of other TLRs14.
Here, we demonstrated that preformed α-syn fibril (PFF) stimulated the interaction of TLR2 with its downstream partner MyD88 and that wild-type (wt) TIDM peptide reduced such interaction and decreased the generation of proinflammatory molecules in PFF-stimulated microglia without altering microglial phagocytic activity. Accordingly, the wtTIDM peptide inhibited α-syn spreading in the brain, prevented activation of glial cells, and attenuated parkinsonian pathologies in PFF-seeded sporadic model of PD. Furthermore, genetic deletion of TLR2 also halted the spreading of α-syn in the PFF-seeded brain, indicating an indispensable role of TLR2 in α-syn spreading. From the molecular level, we found that microglia-derived proinflammatory molecules increased neuronal α-syn expression via NF-κB-dependent transcriptional events and that blocking NF-κB activation in the brain by nasal NEMO-binding domain (NBD) peptide also decreased α-syn spreading and protected DAergic neurons in PFF-seeded A53T mice. These results suggest that the TLR2/MyD88/NF-κB pathway plays an important role in α-syn spreading and that targeting this pathway may have therapeutic importance for different α-synucleinopathies such as PD, MSA, and DLB.
Inhibition of PFF-induced TLR2 activation by wtTIDM peptide
The α-syn monomers were subjected to fibril formation under in vitro conditions over 7 days at 37 °C and then sonicated to produce short-length fibrils of the protein. Electron microscopy was performed to visualize the fibrillar structure of the protein (Fig. 1a). The data showed the thread-like structure of α-syn signifying successful conversion of the monomers into fibrils. Further SDS-PAGE and immunoblotting were performed with pure α-syn fibrils, where the presence of multimeric forms (38 kD and 50 kD) of the protein was observed (Fig. 1b). Next, to monitor PFF-induced TLR2 activation in microglia, mouse BV-2 microglial cells were treated with PFF, and TLR2-MyD88 interaction was evaluated by immunoprecipitation-coupled western blot. The findings exhibited remarkable enhancement in TLR2 and MyD88 interaction induced by PFF. However, this interaction was significantly inhibited by wtTIDM, but not by mTIDM, peptide (Fig. 1c, d and Supplementary Fig. S1). Since increased TLR2-MyD88 interaction leads to the activation of NF-κB, we monitored the effect of TIDM peptides on PFF-induced activation of NF-κB in BV-2 cells. Activation of NF-κB was monitored by both DNA-binding and transcriptional activities. While the DNA-binding activity of NF-κB was evaluated by the formation of a distinct and specific complex in electrophoretic mobility shift assay (EMSA), the transcriptional activity of NF-κB was monitored by the expression of luciferase from a reporter construct, pNF-κB-Luc. As evidenced from EMSA (Fig. 1e) and luciferase activity (Fig. 1f), PFF-treated BV-2 cells exhibited marked activation of NF-κB, and this was inhibited by wtTIDM, but not mTIDM, peptide. Since NF-κB is a proinflammatory transcription factor, we also monitored the expression of proinflammatory molecules such as inducible nitric oxide synthase (iNOS) and interleukin-1β (IL-1β), which are driven by NF-κB activation. Consistent to the induction of NF-κB activation, PFF alone led to marked mRNA expression of iNOS (Fig. 1g) and IL-1β (Fig. 1h) in primary microglia. However, wtTIDM, but not mTIDM, peptide markedly inhibited PFF-induced expression of iNOS and IL-1β in microglia (Fig. 1g, h). Overall, the findings indicate PFF-induced activation of TLR2 and consequent generation of inflammatory events in BV-2 cells and primary microglia can be attenuated by wtTIDM peptide.
Microglial phagocytosis remains unaffected by TIDM
Microglia serves as scavenging cells in the CNS for the degradation of extracellular debris and protein aggregates via phagocytosis. However, many anti-inflammatory molecules are known to inhibit microglial phagocytosis. Therefore, here, we examined the effect of TLR2 inhibition on phagocytosis. Phagocytic activity was monitored by using FITC-tagged monomeric α-syn in primary microglia isolated from WT and TLR2−/− mice. It is clearly evident that TLR2−/− microglia is less efficient in internalizing extracellular α-syn as compared to the WT microglia (Fig. 1i, j). These results are consistent with a previous study15 showing that TLR2 ablation can compromise microglial phagocytosis. It further suggests that the presence of functional TLR2 is essential for phagocytosis as it is one of the receptors of α-syn. Interestingly, either wtTIDM- or mTIDM-treated WT microglia phagocytose extracellular α-syn to a similar extent as the untreated cells (Fig. 1k, m), suggesting that wtTIDM peptide does not alter microglial phagocytosis. Next, we monitored phagocytosis in LPS-stimulated microglia, where LPS was added to the cells 30 min after TIDM administration. As expected, we observed an increase in α-syn phagocytosis by LPS-stimulated microglia (Fig. 1l, m). However, either wtTIDM- or mTIDM-pretreated LPS-stimulated microglia also internalized a comparable amount of extracellular α-syn similar to only LPS-stimulated cells. To ensure that TIDM-mediated TLR2 inhibition does not hamper the microglial phagocytosis, we also performed this test using FITC-tagged fluorescence latex beads in both un-stimulated (Supplementary Fig. S2a) and LPS-stimulated (Supplementary Fig. S2b) primary microglia. Again, we found similar phagocytosis efficiency of external beads by microglia irrespective of TIDM treatment (Supplementary Fig. S2c). Although the absence of TLR2 hampered microglial phagocytosis, specific targeting of the interaction between intracellular MyD88 and TLR2 by wtTIDM peptide did not interfere with the phagocytic activity of microglia. These results suggest that selective inhibition of TLR2 activation by wtTIDM peptide can be an effective strategy to prevent PFF-induced microglial inflammation without hampering microglial phagocytosis.
Intranasal administration of wtTIDM peptide reduces gliosis in the SN of PFF-seeded mice
Before testing wtTIDM peptide for controlling α-synucleinopathy, we monitored the level of TLR2 in the CNS of A53T mice. It was found that TH neurons (Supplementary Fig. S3a, c), Iba1-positive and P2RY12-positive microglia (Supplementary Fig. S3b, d–f) and GFAP-positive astrocytes (Supplementary Fig. S3g, h) in the SN of A53T mice expressed a significantly higher level of TLR2 compared to the respective cell types in the non-transgenic (nTg) animals. Prior to conducting experiments in A53T animals, we evaluated the bioavailability of TIDM peptides in the brain of TIDM-treated B6C3 mice by using Alexa-680-labeled TIDM peptides. Infrared scanning of mice demonstrated the presence of both wtTIDM and mTIDM peptides in the brain, although no signal was detected in the brain of only Alexa-680-treated animals, confirming the specificity of the experiment (Supplementary Fig. S4a). Furthermore, serial blocks of tissues were also scanned and showed remarkably higher availability of these peptides in the cerebellum, midbrain, and in the cortex (Supplementary Fig. S4b, c). Next, we monitored the effect of wtTIDM peptide in PFF-seeded A53T mice. However, unlike other studies where M20 mice16,17 or M83+/− mice18 were used for PFF seeding, we used M83+/+ (A53T+/+) mice for this experiment, because in the presence of a mutated form of the human α-syn gene in both the alleles, exogenous PFF-mediated pathology might develop much faster by homotropic species-specific interaction of α-syn18. The A53T animals start showing α-syn aggregation following 4 months of age, although no motor behavioral changes or dopaminergic cell death is found even in the later stage of the lifespan. Therefore, to induce a parkinsonian model, we injected PFF in the internal capsule (IC) region of striatum in both hemispheres of the mice (Supplementary Fig. S5a), and following 2 months of PFF seeding, animals received nasal delivery of 0.1 mg/kg/d of wtTIDM or mTIDM for the next 1 month. The total time span following PFF-injection was kept for 3 months based on earlier reports where researchers have shown the formation of α-syn pathology in SN following just one month of PFF induction17. The experimental animals were sacrificed at the age of 6 months and several biochemical tests were conducted from nigral and striatal tissues to find out the effect of TIDM treatment on PFF-induced pathology (Supplementary Fig. S5b). As wtTIDM peptide initially showed anti-inflammatory effects in PFF-exposed primary microglia, we examined the efficacy of this peptide in preventing glial inflammation in vivo in SN of PFF-seeded animals. It was found that nTg mice had a very low basal level of microglia (Supplementary Fig. S5c, d) and astroglia (Supplementary Fig. S7a, b) in the SN. Although some increase in the number of glial cells was observed in 6-month-old A53T mice receiving only PBS, the number of microglia and astroglia was found to be much greater in SN of PFF-seeded mouse brain (Supplementary Figs. S5c, d, and S7a, b). Increased number of glial cells also accompanied with a higher level of iNOS expression in both microglia and astroglia (Supplementary Figs. S5c, e and S7a, c) indicating aggravated gliosis and inflammation induced by PFF seeding. In addition, to further confirm PFF-induced microgliosis in SN, immunostaining was conducted for microglia-specific marker P2RY12 and the findings demonstrated an exaggerated number of P2RY12-positive cells in the SN of PFF-induced mice (Supplementary Fig. S6a, b). Interestingly, glial activation in terms of a number of glial cells as well as iNOS expression was remarkably suppressed in SN of PFF-seeded mice treated with wtTIDM, but not mTIDM, peptide (Supplementary Figs. S5c, e, S6b, and S7a, c). Furthermore, the whole tissue protein level of important inflammatory glial markers such as Iba1, IL-1β, iNOS, and GFAP (Supplementary Fig. S5f–j) was assessed by immunoblotting and the level of these markers were also found to be significantly increased in SN of PFF-seeded mice as compared to PBS-injected A53T mice. However, intranasal treatment of PFF-seeded mice with wtTIDM, but not mTIDM, peptide led to suppression of these inflammatory molecules (Supplementary Fig. S5f–j).
Intranasal administration of wtTIDM peptide reduces α-syn spreading from striatum to nigra and motor cortex in PFF-seeded mice
Since glial activation occurs in parallel with the spreading of pathological α-syn16 and wtTIDM inhibited PFF-induced glial activation in the SN, we examined the effect of TIDM on α-syn spreading in the brain. After PFF seeding in the IC, we observed a several-fold higher level of Triton X-100 insoluble form of α-syn in the SN as compared to the age-matched PBS-injected control group (Fig. 2b, d). However, intranasal wtTIDM peptide significantly decreased the detergent-insoluble form of α-syn in the SN, without exhibiting any visible change in the detergent soluble fraction (Fig. 2a, c). The finding was further substantiated by immunostaining of phosphoserine 129 form of α-syn (pSyn129) in the SN that demonstrated aggravated pSyn129 level in SN of PFF-seeded mice with both somatic and neuritic pathology. Again, the pSyn129 content was significantly reduced by treatment with wtTIDM, but not mTIDM (Fig. 2e, f). We also evaluated the level of pathological pSyn129 in the motor cortex and found the presence of thread-like fibrillar pSyn129 in cortical neurons of PFF-injected mice (Fig. 2g, h). However, parallel to SN, the level of pSyn129 drastically reduced in the motor cortex after wtTIDM administration (Fig. 2g, h). Total α-syn level in the motor cortex was evaluated by immunoblotting, which demonstrated the presence of higher molecular weight oligomeric forms in the detergent-insoluble protein fraction in PFF-injected mice (Fig. 2j, l) with no change in Triton X-100 soluble α-syn (Fig. 2i, k). Following wtTIDM administration, a significant reduction of monomeric and oligomeric α-syn was found only in detergent-insoluble fractions. On the other hand, mTIDM peptide failed to reduce insoluble α-syn in PFF-seeded brains (Fig. 2j, l). We also monitored pathological pSyn129 in the hippocampus (Supplementary Fig. S8a, c) and rostral striatum (Supplementary Fig. S8b, d) and found elevated level of pSyn129 in both the regions in PFF-seeded mice as evidenced by the presence of dark-stained pSyn129+ neurons in the hippocampal CA1 region and dorsal striatum, which was inhibited by treatment with wtTIDM, but not by mTIDM. Together, these results suggest that intranasal wtTIDM is capable of preventing α-syn spreading in the brain.
Ablation of TLR2 reduces α-syn spreading in PFF-seeded mice
To further confirm the involvement of TLR2 in α-syn spreading in the brain, A53T mice lacking TLR2 (A53TΔTLR2) were prepared by crossbreeding A53T+/+ and TLR2−/− animals (Fig. 3a). Two months old A53T and A53TΔTLR2 animals were seeded with PFF and following 3 months of brain surgery, experiments were performed. No significant change in soluble α-syn was found between A53T + PFF and A53TΔTLR2 + PFF groups (Fig. 3b, d). The insoluble α-syn level was significantly higher in SN of PFF-seeded A53T animals than in the PBS-injected group (Fig. 3c, e). However, detergent-insoluble α-syn content was significantly less in SN of A53TΔTLR2 + PFF compared to A53T + PFF mice (Fig. 3c, e). The pronounced spreading of α-syn was validated further in SN of PFF-seeded A53T mice by pSyn129 staining. PFF-seeded A53TΔTLR2 mice exhibited limited spreading in the SN region, and the accumulation of pSyn129 was significantly less than the PFF-seeded A53T mice (Fig. 3f, g). Simultaneously, A53TΔTLR2 + PFF mice also showed remarkably less pSyn129 accumulation in the motor cortex than A53T + PFF mice (Fig. 3h, i). These findings clearly indicate that the spreading of pathological α-syn in different brain regions is significantly reduced in the absence of functional TLR2.
Attenuation of α-syn spreading-induced DAergic neuronal death and PD pathologies by intranasal administration of wtTIDM
PFF microinjection into IC was earlier shown to cause DAergic neuronal death in SN and it happens with gratuitous induction of gliosis16,18. Our findings have so far revealed that wtTIDM could effectively lower gliosis and reduce the spreading of pathological α-syn from striatum to nigra in PFF-seeded mice. Therefore, we monitored the vulnerability of DAergic neurons. However, prior to examining TH neuronal content in SN, we evaluated caspase 3 activation in nigral cells by immunostaining for cleaved caspase 3 to find out the induction of cell death triggered by α-syn in SN. We observed an exaggerated level of cleaved caspase 3 (Supplementary Fig. S9a, b, d), which correlated well with the enhanced aggregated level of α-syn in SN of PFF-induced animals (Supplementary Fig. S9a–c). In contrast, TH expression in surviving DAergic neurons of SN was significantly reduced in these animals (Supplementary Fig. S9b, e). This finding is of utmost importance as aggregated α-syn level parallels with enhanced caspase 3 and at the same time with decreased TH. In accordance with this finding, we found considerable loss of TH neurons in the nigra of PFF-seeded A53T mice as compared to PBS-microinjected mice. However, intranasal administration of wtTIDM, but not mTIDM, peptide significantly attenuated α-syn aggregation, caspase 3 activation, and the death of TH neurons (Supplementary Fig. S9). Parallel to this finding, the whole tissue TH expression was also found to be much higher in wtTIDM-treated PFF-seeded mice than either untreated or mTIDM-treated PFF-seeded mice (Fig. 4c, d). Next, we monitored TH fibers in the striatum that also revealed remarkable protection of TH fibers in wtTIDM-treated mice (Fig. 4e, f). This observation was further confirmed by western blot analysis (Fig. 4g, h). Since the restoration of TH cell body in SN and terminals in striatum should result in a greater level of DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), HPLC analyses for neurotransmitters were conducted from striatal tissues. As expected, PFF seeding caused around 40–50% loss of DA content in the striatum, which was significantly prevented by wtTIDM treatment (Fig. 4i–k). Finally, motor coordination of these animals was performed to check the functional outcome of wtTIDM-mediated restoration of nigral TH neurons and striatal DA level. Control 6 months old PBS-injected A53T animals did not show any motor abnormalities including rearing and in rotarod test compared to nTg group (Fig. 4l–p). However, compromised forepaw use and feet movement were clearly seen in PFF-seeded A53T mice, as evidenced by less number of rearing and poor performances in rotarod (Fig. 4l, m) and it is supported by earlier reports showing reduced forelimb and forelimb plus hindlimb activity of PFF-seeded animals17,19. Interestingly, wtTIDM treatment significantly corrected the behavioral abnormalities of PFF-seeded mice, whereas mTIDM-treated mice did not show any improvement in motor behavior. Overall, the findings indicate prevention of PFF-induced nigrostriatal pathology and improvement in motor behavior by intranasal wtTIDM treatment.
The wtTIDM peptide prevents α-syn-induced pathology in aged A53T model of α-synucleinopathy
After establishing the protective effect of wtTIDM against PFF-induced pathology, we extended the research in a more progressive model of α-synucleinopathy, A53T, which constitutively expresses the mutant form of human α-syn. At 9 months of age, A53T animals exhibit considerable glial activation and deposition of α-syn aggregates in the form of LBs in the affected regions of the brain including SN and hippocampus. These mice exhibit hyperactive behavior from 3 to 6 months of age, but the pathology becomes prominent with deficits in movement behavior at 9 months of age without demonstrating significant loss of nigral TH neurons20. Therefore, 8-months old A53T animals were given nasal delivery of wtTIDM and mTIDM (0.1 mg/kg daily) for the next one month followed by monitoring biochemical and behavioral parameters. Similar to the findings obtained from PFF-seeded mice, downregulation in the level of Triton X-100 insoluble pathological form of α-syn in SN was found in wtTIDM-administered animals, but not in an mTIDM-treated group (Supplementary Fig. S10c, d), although the soluble form of the protein was not altered by TIDM administration (Supplementary Fig. S10a, b). Moreover, the overall content and size of α-syn aggregates in nigral DAergic neurons were found to be significantly depleted by wtTIDM treatment in A53T animals (Supplementary Fig. S10e–h). Parallel to α-syn depletion, microglial inflammation was also inhibited as evidenced by lower expression of microglial iNOS (Supplementary Fig. S10i, j), decreased protein level of iNOS (Supplementary Fig. S10k, l) and IL-1β (Supplementary Fig. S10k, m) in the SN of a wtTIDM-treated group. In contrary, mTIDM-treated A53T animals did not exhibit any reduction in the level of proinflammatory molecules. Lastly, behavioral tests were conducted in the aged A53T animals. As expected, A53T animals exhibited poor performance in the pole test as these mice took a longer time to turn downward (pole turn time) on the pole and to reach the base (climb downtime) of the pole (Supplementary Fig. S10n, o). However, consistent with the suppression of α-syn spreading, wtTIDM treatment significantly improved the performance of A53T animals in the pole test.
The wtTIDM peptide reduces α-synucleinopathy in A53T mice via TLR2
To further confirm that wtTIDM exerts its anti-inflammatory and anti-proteinopathy effects via interaction with TLR2, 9-months-old A53TΔTLR2 control and wtTIDM-treated A53TΔTLR2 animals were compared with age-matched A53T mice with respect to the level of α-syn aggregates in neurons, the extent of gliosis, and lastly the motor behavior. In the absence of functional TLR2 protein, α-syn could not induce exaggerated microgliosis as evident from Iba1+ microglia in the SN of A53TΔTLR2 mice and age-matched A53T mice (Supplementary Fig. S11i, j). Reduced microgliosis was accompanied by significant downregulation of Triton X-100 insoluble form of α-syn in SN of A53TΔTLR2 mice as compared to the A53T animals (Supplementary Fig. S11c, d). No significant downregulation of detergent soluble α-syn was found in A53TΔTLR2 mice (Supplementary Fig. S11a, b). Similarly lower content of TH neuron-specific α-syn aggregates was found in SN of A53TΔTLR2 mice (Supplementary Fig. S11e–h). Lack of glial inflammation in double transgenic animals was further confirmed by western blot analysis of iNOS (Supplementary Fig. S11k–l) and IL-1β (Supplementary Fig. S11k, m). Interestingly, in contrast to A53T mice, wtTIDM peptide remained unable to further decrease pathological features including α-syn aggregate level in midbrain tissues (Supplementary Fig. S11c, d), in TH neurons (Supplementary Fig. S11e–h) and proinflammatory molecules in A53TΔTLR2 mice (Supplementary Fig. S11k, m). Finally, A53TΔTLR2 mice performed significantly better than A53T mice in the pole test. However, wtTIDM peptide treatment did not improve movement activities of A53TΔTLR2 mice (Supplementary Fig. S11n, o). These results suggest that in the absence of functional TLR2 protein, wtTIDM does not exhibit any neuroprotective effect in A53T mice.
Proinflammatory cytokines upregulate the expression of α-syn in neuronal cells
Next, we investigated molecular mechanisms by which TLR2 is coupled to α-synucleinopathy. We have convincingly showed that both microglial inflammation and spreading of pathological α-syn happen simultaneously in the brain of different models of α-synucleinopathy and that TLR2 is capable of controlling both pathological events. An increase in the level of α-syn is a prerequisite for α-synucleinopathy. However, it is not clear whether microglia-derived proinflammatory molecules directly modulate α-syn levels in neurons. Since activated microglia release different proinflammatory cytokines such as IL-1β and TNFα, mouse MN9D neuronal cells were treated with different concentrations of IL-1β and TNFα followed by monitoring the level of α-syn by western blot. The data demonstrated that both IL-1β (Fig. 5a, b) and TNFα (Supplementary Fig. S12a, b) increased α-syn protein level in a dose-dependent manner. Immunofluorescence analysis also showed that IL-1β (Fig. 5c) and TNFα (Supplementary Fig. S12c) were capable of increasing the level of α-syn protein in MN9D cells.
Proinflammatory cytokines upregulate α-syn in mouse and human neuronal cells via NF-κB
Next, we investigated mechanisms by which proinflammatory cytokines upregulate α-syn in neurons. Since proinflammatory cytokines induce the activation of NF-κB, we probed the α-syn gene promoter for NF-κB binding site by MatInspector search and found a consensus NF-κB binding site within −335 and −350 bp. Therefore, we examined the role of NF-κB activation in the expression of α-syn. The DNA-binding activity of NF-κB was evaluated by the formation of a distinct and specific complex in a gel shift DNA-binding assay. Treatment of MN9D cells with IL-1β resulted in the induction of DNA-binding activity of NF-κB (Fig. 5d). Similarly, IL-1β also induced the transcriptional activity of NF-κB as evident by luciferase activity from PBIIx-Luc construct with maximum activation seen at a concentration of 20 ng/ml (Fig. 5e). Next, to confirm the involvement of NF-κB in the expression of α-syn, we used wild type NF-κB essential modifier (NEMO) binding domain (wtNBD) peptide, known to specifically inhibit the induction of NF-κB activation21,22. Inhibition of α-syn mRNA expression by wtNBD, but not mNBD, peptide in neuronal cells treated with IL-1β (Fig. 5f) and TNFα (Supplementary Fig. S12d) suggests that proinflammatory cytokines stimulate α-syn expression in neurons via NF-κB.
Next, to test whether NF-κB transcriptionally regulates α-syn expression, the α-syn promoter (pα-syn-WT) containing the NF-κB binding site was cloned into the PGL3 enhancer vector (Fig. 5g). We also mutated the core NF-κB binding site and the mutated promoter construct (pα-syn-Mut) was cloned into the PGL3 vector (Fig. 5g). We found that IL-1β (Fig. 5h) and TNF-α (Supplementary Fig. S12e) markedly induced luciferase activity driven by wild type (pα-syn-WT), but not mutated (pα-syn-Mut), α-syn promoter. To further confirm the transcriptional regulation of α-syn promoter by NF-κB, we monitored the recruitment of NF-κB to the α-syn promoter by ChIP analysis. The classical NF-κB is a heterodimer of p65 and p5021,22 and 1 h stimulation with IL-1β was sufficient to induce the recruitment of both p65 and p50 to the α-syn promoter in MN9D cells (Fig. 5i, j). Since histone acetyltransferases such as CREB-binding protein (CBP) and p300, play an important role in transcriptional activities, we investigated if CBP and p300 were also involved in IL-1β-induced transcription of the α-syn gene. As evident from PCR (Fig. 5i) and real-time PCR (Fig. 5j), IL-1β stimulation induced the recruitment of p300, but not CBP, to the α-syn gene promoter. Consistent with the recruitment of p65, p50, and p300, IL-1β was also able to recruit RNA polymerase (RNA Pol) to the α-syn gene promoter (Fig. 5i, j). These results are specific as we did not see any amplification product in any of the immuno-precipitates obtained with control IgG (Fig. 5i, j). It indicates that IL-1β is capable of inducing the recruitment of p65, p50, p300, and RNA pol to mouse α-syn promoter in mouse MN9D neuronal cells (Fig. 5k).
Next, we examined whether NF-κB was also involved in IL-1β-induced expression of α-syn in human SH-SY5Y neuronal cells. Similar to mouse α-syn promoter, the human α-syn promoter also harbors a consensus NF-κB binding site (Supplementary Fig. S13a). Accordingly, IL-1β also induced the DNA-binding (Supplementary Fig. S13b) and transcriptional (Supplementary Fig. S13c) activities of NF-κB in SH-SY5Y cells. Inhibition of IL-1β-induced upregulation of monomeric and oligomeric forms of α-syn protein in SH-SY5Y cells by wtNBD, but not mNBD, peptide suggests that similar to mouse neuronal cells, IL-1β also requires NF-κB to increase α-syn in human neuronal cells (Supplementary Fig. S13d–f). Finally, a significant amount of p65, p50, p300, and RNA Pol was found to be recruited to the human α-syn promoter in IL-1β-treated SH-SY5Y cells (Supplementary Fig. S13g, h), highlighting the importance of NF-κB in IL-1β-induced transcription of the human α-syn gene.
Is activation of NF-κB sufficient for the induction of α-syn expression?
In addition to inducing the activation of NF-κB, proinflammatory molecules are known to transduce many other signaling pathways. Therefore, we examined whether activation of NF-κB alone is sufficient to induce the expression of α-syn in neuronal cells. The p65 (RelA) subunit of NF-κB, cloned in pcDNA3, was over-expressed in MN9D cells followed by monitoring the level of α-syn. It was found that the overexpression of p65 alone markedly increased the level of α-syn in MN9D neuronal cells (Supplementary Fig. S14a, b). These results were specific as the empty vector remained unable to increase α-syn in MN9D cells (Supplementary Fig. S14a, b). These results suggest that activation of NF-κB is sufficient to increase the expression of α-syn in neurons.
Etiological reagents of different neurodegenerative disorders upregulate the activation of α-syn promoter via NF-κB
Along with primary α-synucleinopathies (PD, DLB, and MSA), α-syn pathology is observed in various inflammatory conditions associated with viral encephalopathy, multiple sclerosis (MS), HIV-associated neurocognitive disorders (HAND), etc.23,24. Because IL-1β and TNFα upregulated the activation of α-syn promoter in neuronal cells, we were prompted to investigate whether different proinflammatory molecules were also capable of upregulating α-syn promoter. Therefore, MN9D neuronal cells transfected with wild type (pα-syn-WT-Luc) and mutated (pα-syn-Mut-Luc) α-syn promoter-driven reporter constructs were stimulated with dsRNA in the form of poly IC (one of the etiological reagents for viral encephalopathy), HIV-1 Tat (one of the etiological reagents for HAND), MPP+ (Parkinsonian toxin), bacterial lipopolysaccharides or LPS (a prototype inflammatory stimulus), CpG oligonucleotide or ODN (bacterial infection-associated inflammation), and IFNγ (Th1 cytokine associated to MS). Similar to IL-1β and TNFα, MPP + (Supplementary Fig. S15a), LPS (Supplementary Fig. S15b), Tat (Supplementary Fig. S15c), ODN (Supplementary Fig. S15d), and poly IC (Supplementary Fig. S15e) markedly induced luciferase activity driven by wild type (pα-syn-WT), but not mutated (pα-syn-Mut), α-syn promoter. In contrast, IFNγ induced the activation of both wild type (pα-syn-WT-Luc) and mutated (pα-syn-Mut-Luc) α-syn promoters (Supplementary Fig. S13f). These results suggest that MPP+ , LPS, Tat, ODN, and poly IC, but not IFNγ, require NF-κB for the activation of α-syn promoter in neurons.
Microglia-derived proinflammatory molecules upregulate α-syn expression in primary DAergic neurons
After establishing the molecular mechanism behind inflammatory molecule-mediated α-syn transcriptional upregulation in MN9D and SH-SY5Y cells, we further validated the phenomenon in mouse primary DAergic neurons. In this case, primary microglia pretreated with wtTIDM or mTIDM peptide for 30 min were challenged with PFF. Following 24 h of PFF exposure, we measured microglia-secreted inflammatory molecules such as IL-1β and TNF-α from the spent medium by sandwich ELISA. The results showed a marked increase in the level of these cytokines in PFF-treated microglia compared to the untreated control. However, wtTIDM, but not mTIDM, peptide pre-treatment significantly reduced the level of microglia-secreted IL-1β and TNFα in the media (Supplementary Fig. S16a, b). Then to evaluate the effect of microglia-secreted inflammatory molecules on the expression of neuronal α-syn, we performed the co-culture analysis with primary microglia and midbrain DAergic neurons. As described above, microglia were treated with TIDM for 30 min followed by stimulation with PFF. After 12 h of PFF exposure, the insert containing the microglia was placed on top of the neuronal culture so that microglia-derived proinflammatory molecules can come in contact with the neurons (Fig. 6a). Firstly, following 3 h of microglia-neuron co-culture, the status of NF-κB activation was assessed in TH+ DAergic neurons by immunostaining for Ser536 phospho-p65. The findings demonstrated significant upregulation of phospho-p65 following PFF exposure (Fig. 6b). Interestingly, neurons co-cultured with wtTIDM-treated microglia showed reduced expression of phospho-p65, but it was not found in the case of mTIDM treatment (Fig. 6b). Furthermore, we evaluated α-syn mRNA expression in primary neurons following 6 h of co-culturing with PFF-treated microglia. As expected, PFF-exposed neurons exhibited around 6-fold increase in α-syn expression compared to the control group. However, α-syn expression markedly decreased in PFF-insulted neurons upon treatment with wtTIDM, but not mTIDM (Fig. 6c). Lastly, α-syn protein expression was assessed by immunostaining in TH+ neurons, where parallel to the α-syn mRNA expression, we found higher α-syn protein level following co-culturing with PFF-treated microglia. Interestingly, the α-syn protein level was markedly reduced in neurons cultured with wtTIDM-treated microglia (Fig. 6d, e). These data suggest that under PFF exposure, microglia-secreted proinflammatory molecules stimulate the expression of neuronal α-syn via activating NF-κB and that wtTIDM pre-treatment inhibits the generation of proinflammatory molecules by microglia resulting in reduced upregulation of neuronal α-syn expression. To further strengthen the role of NF-κB activation in mediating inflammation-induced upregulation of neuronal α-syn, we conducted another microglia-neuron co-culture experiment, where microglia was initially exposed to PFF for 12 h and then co-cultured with neurons, but 30 min prior to co-culturing, neurons were treated with either wtNBD or mNBD peptides (Supplementary Fig. S14c). Expression analysis for α-syn mRNA and protein in these neurons demonstrated a marked increase in PFF-exposed neurons. However, wtNBD-treated neurons could significantly attenuate the PFF-induced upregulation of α-syn expression that was not observed in mNBD-treated neurons (Supplementary Fig. S16d–f).
The wtTIDM peptide prevents NF-κB activation in nigral DAergic neurons
As wtTIDM was found to inhibit PFF-induced activation of NF-κB in primary DAergic neurons, it was necessary to evaluate whether the finding was also recapitulated in vivo. We assessed the level of Ser536 phospho-p65 expression in nigral neurons by immunofluorescence analysis. The data demonstrated a significant increase in phospho-p65 level in TH+ neurons of PFF-injected mice (Fig. 6f, g). However, activated p65 level in nigral neurons was markedly less in wtTIDM-treated PFF-induced animals that was not observed in the case of mTIDM-treated animals (Fig. 6f, g). To confirm the involvement of NF-κB in the expression of α-syn further, we examined the recruitment of NF-κB to α-syn gene promoter in vivo in the SN by in situ ChIP. We found marked enrollment of p65 and p50 to the α-syn gene promoter in the SN of PFF-treated mice as compared to PBS-injected mice (Fig. 6h, i). Parallel to this, the binding of p300 and RNA polymerase II to α-syn promoter was also found to be significantly elevated in the PFF-insulted brain with respect to the PBS-injected samples (Fig. 6h, i). It indicates transcriptional activation of α-syn gene via activation of classical NF-κB following PFF induction. Interestingly, the recruitment of p65, p50, p300, and RNA polymerase II was found to be greatly reduced in wtTIDM-treated, but not mTIDM-treated, PFF-insulted mice (Fig. 6h, i). Collectively, these results indicate that wtTIDM peptide inhibit NF-κB-mediated transcriptional activation of α-syn gene.
Intranasal administration of NEMO-binding domain (NBD) peptide reduces α-syn spreading from striatum to nigra in PFF-seeded mice
Findings presented above indicate that PFF-induced TLR2 activation causes the generation of microglial proinflammatory molecules to upregulate the expression of α-syn in neurons via NF-κB activation. This prompted us to investigate the role of NF-κB in α-syn spreading in the brain. The wtNBD peptide is a specific inhibitor of NF-κB activation22 and we have demonstrated that after intranasal administration, wtNBD peptide enters into the brain25. Therefore, here, we examined the effect of intranasal wtNBD on α-syn spreading in the brain. Following 1 month of wtNBD administration, NF-κB activation in SN and spreading of α-syn in both SN and motor cortex were monitored. We found marked upregulation of microglial acetylated p65 level in the SN of PFF-seeded mice compared to the PBS-injected mice (Supplementary Fig. S17a, b). However, acetylated p65 level was significantly decreased in wtNBD-treated mice brain (Supplementary Fig. S17a, b). As described above, PFF seeding resulted in exaggerated accumulation of pSyn129 in nigral neurons (Fig. 7a, b). However, intranasal wtNBD peptide drastically reduced the level of pSyn129 in these neurons, which is reflected by the relative optical density measurement of pSyn129 in SN (Fig. 7a, b). This observation was also verified by immunoblotting, where PFF-seeded mice exhibited the presence of a higher level of detergent-insoluble form of α-syn than PBS-injected mice (Fig. 7d, f). However, following wtNBD treatment α-syn contents in both soluble and insoluble fractions were significantly reduced (Fig. 7c–f). Similar to nigra, wtNBD peptide also reduced the spreading of α-syn in the motor cortex as evidenced by reduced accumulation of pSyn129 in cortical neurons of wtNBD-treated PFF-seeded mice as compared to saline-treated PFF-seeded mice (Fig. 7g, h).
Intranasal NBD peptide protects DAergic neurons and improves locomotor activities in PFF-seeded mice
Next, we monitored the effect of intranasal wtNBD on PFF-induced parkinsonian pathologies. Significant reduction in the number of TH neurons (Supplementary Fig. S18a) as well as nigral TH protein level (Supplementary Fig. S18b, c) was seen in PFF-seeded mice as compared to the PBS-injected group. The demise of nigral TH neurons resulted in the depletion of neurotransmitters in the striatum of PFF-seeded animals (Supplementary Fig. S18d–f). Interestingly, nigral TH neurons, TH protein level, and the striatal DA level were significantly protected in wtNBD-treated mice (Supplementary Fig. S18a–f). As expected, PFF seeding also resulted in a deficit in motor performance of A53T animals as demonstrated by rearing (Supplementary Fig. S18g) and rotarod analysis (Supplementary Fig. S18h). However, concomitant with DAergic neuronal protection, wtNBD treatment significantly inhibited the movement deficits in PFF-seeded mice. These results suggest that intranasal wtNBD peptide was capable of protecting DAergic neurons and improving locomotor activities in PFF-seeded mice.
Prion-like spreading of pathological α-syn aggregates in the brain of α-synucleinopathy such as PD, MSA, and DLB has been well manifested by several studies6,19,26. However, mechanisms by which α-syn spreading occurs in the brain are poorly understood. It is well established that seeding of α-syn fibrils in the striatum causes accumulation of pathological form of the protein associated with extensive gliosis in SN that make the tissue environment hostile for the surviving DAergic neurons27,28,29. An overwhelming level of α-syn leads to the secretion of this protein from neurons30,31,32,33, which then activates microglia via activation of NF-κB activation and upregulation of proinflammatory molecules34. In addition, astroglial activation during the course of PD progression happens via reactive microglia-derived factors16 and also by the direct influence of neuron-released α-syn, ultimately augmenting the secretion of several proinflammatory factors in the brain35. Therefore, aggravated glial activation coincides with increased α-syn expression in the brain. It is also consistent with the previous report that glial activation precedes α-syn pathology in a mouse model of PD36.
Recently, we have delineated that a peptide corresponding to the TLR2-interacting domain of MyD88 (TIDM) specifically inhibits the induction of TLR2 activation in microglia without affecting the basal level of either TLR2 or MyD8814. Moreover, the TIDM peptide does not modulate the activation and function of other TLRs14. Here, by using TIDM peptide we describe an important role of induced TLR2-MyD88 signaling in microglial activation and α-syn pathology. First, α-syn PFF increased the association between TLR2 and MyD88 in microglia. This physical association in PFF-stimulated microglia was inhibited by wtTIDM, but not mTIDM, peptide. Second, PFF induced the activation of microglia as evident from the activation of NF-κB and the expression of different proinflammatory molecules. However, selective inhibition of TLR2 by wtTIDM led to attenuation of PFF-induced activation of microglia. Third, as expected, widespread microglial activation was seen in the CNS of PFF-seeded mice and aged A53T Tg mice. Intranasal administration of wtTIDM peptide inhibited microglial activation in both cases. Fourth, wtTIDM peptide treatment also reduced the α-syn spreading and pathology in the CNS of PFF-seeded mice and aged A53T Tg mice. Fifth, the specificity of TLR2 inhibition by wtTIDM in vivo was confirmed by conducting the experiments in A53TΔTLR2 mice, where TLR2 is genetically ablated. A53TΔTLR2 mice did not respond to wtTIDM treatment in terms of both α-synucleionopathy and glial inflammation, indicating the requirement of functional TLR2 protein for the functioning of wtTIDM peptide. Sixth, PFF seeding in the striatum led to the loss of TH expression and simultaneous induction of apoptotic protein as revealed by the abundance of cleaved caspase 3 in surviving DAergic neurons in the nigra and these facts are likely contributing to the depletion of dopamine in the striatum. However, nasal treatment with wtTIDM peptide led to the protection of nigral TH neurons and striatal dopamine. Seventh, wtTIDM, but not mTIDM, peptide also ameliorated functional impairment in PFF-seeded mice. Because TLR2 level is high in the nigra of post-mortem PD brains37, our results suggest that wtTIDM peptide may reduce α-synucleinopathy to slow down the loss of nigrostriatal neurons in patients with PD.
According to Kim et al.7, oligomeric α-syn released from neuron serves as an endogenous agonist of TLR2 to cause paracrine activation of microglia. Accordingly, the non-cell-autonomous neurotoxicity of α-syn is mediated through microglial TLR238. It has been also shown that antagonism of neuronal TLR2 is sufficient for the prevention of α-synucleinopathy15. In the absence of any specific inhibitors, these studies used TLR2−/− mice to study the role of TLR2. Others have used TLR2 antagonizing antibodies to block TLR2 in transgenic animal models of α-synucleinopathy39. However, these approaches suppress the basal level of the entire TLR2 including its extracellular domain. Therefore, the importance of wtTIDM peptide lies in its efficacy to selectively disrupt the interaction between TLR2 and MyD88 without affecting either its basal level or its interaction with extracellular ligands such as α-syn. Moreover, due to the presence of antennapedia homeodomain, wtTIDM peptide is BBB permeable14.
It is also indispensable to address that TLR2 was found to be upregulated in astrocytes of the A53T brain. This finding is in line with the earlier finding that showed an increase in astrocytic TLR2 and induction of several inflammatory molecules following exposure to neuron-derived α-syn10. On the other hand, fibrillar α-syn-mediated microglial activation is also known to activate astrocytes towards the inflammatory phenotype causing secretion of cytokines like IL-1β, TNF-α, IL-6, etc.16. Considering these two points, it can be speculated that astroglial activation may also happen directly in response to α-syn PFF via the TLR2 pathway. Studies have also demonstrated that the expression of antigen-presenting genes is increased in astrocytes upon challenge with α-syn fibrils, indicating the existence of other TLR2-independent pathways in α-syn-exposed astrocytes40.
How does TLR2 couple α-synucleinopathy? The exaggerated level of insoluble α-syn in multiple brain regions of PFF-seeded A53T mice raised the question of whether only the exogenous α-syn PFF spread in the brain or the PFF induces increased expression of endogenous α-syn to potentiate the seeding phenomenon over time. Since TLR2 is coupled to microglial inflammation, to understand the molecular mechanism in greater details, we tested a hypothesis that proinflammatory molecules might be directly involved in the upregulation of endogenous α-syn. In fact, upregulation of α-syn by a wide variety of proinflammatory molecules including cytokines (IL-1β, TNFα, and IFNγ), bacterial components (LPS and ODN), viral mimics and components (poly IC and Tat), and toxin (MPP+) indicates that inflammatory insults are capable of upregulating α-syn in neurons. The presence of NF-κB binding site in the α-syn gene promoter, recruitment of classical NF-κB heterodimeric components (p65 and p50) and associated p300 HAT to the α-syn gene promoter by IL-1β and TNFα, activation of wild type (pα-syn-WT), but not mutated (pα-syn-Mut), α-syn promoter by various proinflammatory molecules, inhibition of cytokine-mediated upregulation of α-syn by wtNBD peptide, and increase in α-syn by overexpression of NF-κB p65 alone clearly suggest that the upregulation of α-syn is regulated in neurons via classical inflammatory signaling (NF-κB) pathway. Accordingly, intranasal wtNBD peptide inhibited α-syn spreading in the brain and protected dopaminergic neurons in PFF-seeded mice. Here, it is important to mention that Th1 cytokine IFNγ is known to function via STAT, but not NF-κB41,42. Accordingly, in contrast to a number of proinflammatory stimuli (IL-1β, TNFα, LPS, ODN, HIV-1 Tat, poly IC, and MPP+), IFNγ induced the activation of α-syn promoter in neuronal cells independent of NF-κB, suggesting that in addition to NF-κB, other inflammatory transcription factor(s) may also be involved in the upregulation of α-syn in neurons.
In summary, we delineated that PFF-induced activation of the TLR2-MyD88 pathway triggered the induction of inflammation and generation of proinflammatory molecules from microglia to further act on neurons and augment endogenous α-syn expression via NF-κB-dependent transcription, ultimately augmenting α-syn pathology in multiple regions of the brain. Accordingly, intranasal administration of wtTIDM (acting at the initial stage to inhibit PFF-induced TLR2 activation) and wtNBD (functioning at the downstream phase to inhibit TLR2-mediated NF-κB activation) peptides decreased α-syn spreading and protected dopamine in PFF-seeded mice. These results suggest that wtTIDM and wtNBD peptide may be used for therapeutic intervention in PD, MSA, and DLB in which microglial activation and α-synucleinopathy play key roles in disease pathogenesis.
Dulbecco’s Modified Eagle Medium (DMEM) medium was purchased from Mediatech (Washington, DC) and fetal bovine serum (FBS) was obtained from Atlas Biologicals (Fort Collins, CO). Antibiotic-antimycotic was purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human α-syn was purchased from Anaspec (Fremont, CA). Rabbit anti-tyrosine hydroxylase (TH) antibody was purchased from Pel-Freeze biologicals (Rogers, AR) and mouse anti-TH antibody was procured from Immunostar (Hudson, WI). Mouse α-syn antibody was purchased from BD Bioscience (San Jose, CA) (Supplementary Table S1). Cy2- and Cy5-conjugated antibodies were obtained from Jackson Immuno-Research Laboratories (West Grove, PA).
Adult C57BL6 mice, TLR2−/− mice (B6.129-Tlr2tm1Kir/J) and A53T α-syn transgenic line M83 (B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J) were purchased from Jackson Laboratories. Animal maintenance and experiments were performed in accordance with the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of the Rush University Medical Center (Chicago, IL). Mice were maintained at room temperatures of 65–75 °F (~18–23 °C) with 40–60% humidity. Mice were kept on a 14/10 h light/dark cycle and given a continuous supply of food and water.
Preparation and validation of α-Syn fibrils
For fibril preparation, α-syn monomers were solubilized in 30 mM Tris-HCl (pH 7.4) at the concentration of 350 µM and rotated continuously in a rotary shaker at 250 rpm at 37 °C for 7 days17,43. Next, the fibrils were briefly sonicated (15 s) at 10% amplitude and were characterized by performing electron microscopy (EM). For EM imaging, 1 µl of stock solution was diluted in 100 µl of phosphate buffer saline (PBS) and this solution was adsorbed to 300-mesh copper, Formvar-coated EM grid, washed, stained with 2% uranyl acetate, and the grid was allowed to be dried for 15–20 min. Imaging was performed at ×100,000 magnification using a JEOL JEM-1220 transmission electron microscope (operating at 80 kV). Digital micrographs were acquired using an Erlangshen ES1000W model 785 CCD camera and Digital Micrograph software (Version 1.7). The fibril formation was also validated by running the samples in 12% SDS-PAGE followed by immunoblotting using anti-α-syn antibodies (BD Bioscience, San Jose, CA).
TIDM and NBD peptides
TIDM and NBD peptides (>99% pure) were synthesized in the custom peptide synthesis facility of Genscript (Piscataway, NJ). TIDM peptides contain the Antennapedia homeodomain (lower case) and six amino acid long MyD88 (upper case) segments44.
Wild type (wt) TIDM: drqikiwfqnrrmkwkkPGAHQK
Mutated (m) TIDM: drqikiwfqnrrmkwkkPGWHQD
Similarly, NBD peptides also contain the Antennapedia homeodomain (lower case) and six amino acid long IKKβ (upper case) segments21,45.
Positions of mutations are underlined.
Mouse BV-2 microglial cells and primary microglia
BV-2 murine microglial cells (a gift from V. Bocchini, University of Perugia, Perugia, Italy) were maintained in DMEM/F-12 medium containing 10% FBS at 37 °C in the incubator. Primary microglia were isolated from mixed glial cultures as described21,46,47. Briefly, brain tissues isolated from 2 to 3 d old mouse pups were dissociated with glass mortar, triturated, passed through the mesh, trypsinized, centrifuged, and mixed glial cells plated in DMEM/F-12 containing 10% fetal bovine serum. On day 9, the mixed glial cultures were washed three times with DMEM/F-12 and subjected to a shake at 240 rpm for 2 h at 37 °C on a rotary shaker to isolate microglia.
Isolation of primary mouse DAergic neurons
Similarly, primary DAergic neurons were also isolated as described48,49. Briefly, pregnant female mice were euthanized via cervical dislocation to get the embryonic pups (embryonic stage 13.5). Embryonic pups were quickly decapitated in serum-free media to isolate the developing nigra tissue, which was milled three times, and the cells centrifuged at 1000 rpm for 10 min. Pelleted tissue was resuspended in fresh serum-free DMEM, washed three times, and cells plated in 6-well plates containing coverslips. Cells were incubated for 8 days at 37 °C with 5% CO2 in complete DMEM containing 20% FBS and antibiotic-antimycotic prior to their use in subsequent experiments.
Western blotting was performed as previously described50,51. Equal amounts of proteins were electrophoresed in 10% or 12% SDS-PAGE and transferred onto a nitrocellulose membrane. The blot was probed with primary antibodies overnight at 4 °C (Supplementary Table S1). The next day primary antibodies were removed and the blots were washed with phosphate buffer saline containing 0.1% Tween-20 (PBST) and corresponding infrared fluorophore-tagged secondary antibodies (1:10,000; Jackson Immuno-Research) were added at room temperature (RT). Finally, blots were scanned with an Odyssey infrared scanner (Li-COR, Lincoln, NE). Band intensities were quantified using ImageJ software (NIH, USA).
BV-2 cells were treated with 10 µM of wtTIDM or mTIDM. After 30 min of TIDM treatment, fibrillar α-syn (0.5 µM or 7 µg/ml) was added to the cells and incubated for 2 h. Following the incubation period, cells were scraped and lysed in RIPA buffer. The cell homogenate was centrifuged at 17,500 × g for 15-min 4 °C, the supernatant was collected and protein was estimated using the BCA method. The cell lysate was immunoprecipitated with 2 µg of anti-TLR2 or anti-MyD88 or normal IgG (Santa Cruz Biotechnology) overnight at 4 °C, followed by incubation with protein A-agarose for 4 h at 4 °C. Protein A-agarose-antigen-antibody complexes were collected by centrifugation at 10,000 × g for 1 min at 4 °C. The pellets were washed 3–4 times with 1 ml of IP buffer containing 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol, and protease inhibitor cocktails for 20 min each time at 4 °C. Bound proteins were resolved by SDS-PAGE, followed by western blotting with the anti-MyD88 (1:1000, Santa Cruz Biotechnology) and/or anti-TLR2 (1:1000, Abcam). Input from each sample was also run in the western blotting.
Chromatin immunoprecipitation (ChIP) assay
Recruitment of NF-κB to α-syn gene promoters was determined by ChIP assay as described earlier52. Briefly, MN9D and SHY5Y cells were treated with IL-1β under serum-free conditions, and after 1 h of stimulation, cells were fixed by adding formaldehyde (1% final concentration), and cross-linked adducts were resuspended and sonicated. In the case of in vivo ChIP, animals were perfused with 4% paraformaldehyde, midbrain was isolated and DNA was extracted from the tissues using the phenol–chloroform–isopropyl alcohol method of DNA isolation. ChIP was performed on the cell lysate by overnight incubation at 4 °C with 2 µg of anti-p65, anti-p50, anti-CBP, anti-RNA Polymerase II, or anti-p300 antibodies followed by incubation with protein G agarose (Santa Cruz Biotechnology) for 2 h. The beads were washed and incubated with elution buffer. To reverse the cross-linking and purify the DNA, precipitates were incubated in a 65 °C incubator overnight and digested with proteinase K. DNA samples were then purified, precipitated, and the precipitate was washed with 75% ethanol, air-dried, and resuspended in TE buffer. Following primers were used for amplification of chromatin fragments of mouse α-syn gene.
Promoter of α-syn (spanning proximal NF-κB; 237 bp):
Sense: 5′-TGT ACG CCC ACC TCC CAT GTT CC-3′
Antisense: 5′-TCA TGT CAC TTA AGG ATG GGA TGG-3′.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared, and EMSA was performed as described previously53 with some modifications. Briefly, IRDye end-labeled oligonucleotides containing the consensus binding sequence for NF-κB were purchased from Licor Biosciences. Six micrograms of nuclear extract were incubated with binding buffer and with an infrared-labeled probe for 20 min. Subsequently, samples were separated on a 6% polyacrylamide gel in 0.25× TBE buffer (Tris borate-EDTA) and analyzed by the Odyssey Infrared Imaging System (LI-COR Biosciences).
Construction of mouse α-syn promoter-driven reporter construct
Mouse genomic DNA isolated from primary mouse neuron was used as the template during PCR. The 5′-flanking sequence of the mouse α-syn (−1216/+23) gene was isolated by PCR. Primers were designed from GenBank sequences as follows: α-Syn: sense, 5′-acgcgtCCC CCT GCC CCT GCC TGC CCT TG -3′, and antisense, 5′-agatctGTA AGT CCT TTC ATG AAC ACA TC-3′. The sense primer was tagged with a MluI restriction enzyme site, and the antisense primer was tagged with BglII. The PCR was performed using an Advantage-2 PCR kit (Clontech) according to the manufacturer’s instructions. The resulting fragments were gel-purified and ligated into the PGEM-TEasy vector (Promega). These fragments were further subcloned into the PGL3 Enhancer vector after digestion with the corresponding restriction enzymes and verification by sequencing (ACGT Inc. DNA Sequencing Services).
Cloning of α-syn promoter and site-directed mutagenesis
Site-directed mutagenesis was performed as described earlier52 by using the site-directed mutagenesis kit (Stratagene). Two primers in opposite orientations were used to amplify the mutated plasmid in a single PCR. The primer sequence for mutated promoter site was as follows: mutated: sense, 5′-GGG AAC TTG ATG GGG TAG AAA ATG TTT ACGTCC CCT TCT G-3′, and antisense, 5′-CAG AAG GGG ACG TAA ACA TTT TCT ACC CCA TCA AGT TCC C-3′. The PCR product was precipitated with ethanol and then phosphorylated by T4 kinase. The phosphorylated fragment was self-ligated by T4 DNA ligase and digested with restriction enzyme DpnI to eliminate the nonmutated template. The mutated plasmid was cloned and amplified in Escherichia coli (DH5-α strain)-competent cells.
BV-2 cells plated at 50–60% confluence in 12-well plates were transfected with 0.25 µg pNF-κB-Luc construct using Lipofectamine plus (Life Technologies). Following 24 h of transfection, cells were incubated with wtTIDM or mTIDM for 1 h and then exposed to 0.5 μM PFF under serum-free conditions for 2 h. Luciferase activities were analyzed in cell extracts using the Luciferase Assay System kit (Promega) in a TD-20/20 Luminometer (Turner Designs) as described previously52,54. Similarly, neuronal cells plated at 50–60% confluence in 12-well plates were transfected with 0.25 μg of either pα-syn-(WT)-Luc or pα-syn-(Mut)-Luc using Lipofectamine Plus. After 24 h of transfection, cells were stimulated with different agents under serum-free conditions for 6 h. Firefly luciferase activities were analyzed in cell extracts.
ELISA was performed from microglial spent medium to determine the level of secreted IL-1β and TNFα as described before55. The experiment was performed using mouse IL-1β and TNFα-specific ELISA kits following the manufacturer’s protocol (Invitrogen).
Primary microglia isolated from WT and TLR2−/− mice were plated either on glass coverslips or in 96-well plates. Cells were treated with 5 µM of wtTIDM or mTIDM for 30 min and then FITC-tagged monomeric α-syn (Anaspec) at 0.25 µM concentration or FITC-tagged latex beads (Cayman chemicals, MI) at 1:1000 dilution was added in each well. Following α-syn addition, cells were kept for 2 h, and phagocytosis of α-syn by the microglia was measured by immunostaining. For LPS-stimulated microglia, LPS was added after 30 min of TIDM treatment for another 1 h and then α-syn was added to the LPS-stimulated microglia to evaluate the phagocytosis. For immunostaining purposes, cells were washed at least three times with a warm medium and then fixed with 4% paraformaldehyde. Then the fixed cells were processed for immunostaining for Iba1 using the procedure described above. Imaging of cells was performed under Olympus BX41 fluorescence microscope and the green fluorescence obtained from each cell of all the groups was measured using ImageJ. MFI values of LPS-treated groups were compared with the respective controls.
Total RNA was isolated from primary microglia using the Zymogen RNeasy kit following the manufacturer’s protocol. The isolated RNA was reverse transcribed into cDNA and real-time PCR was carried out in ABI-Prism7700 sequence detection system (Applied Biosystems, Foster City, CA) using the SYBR green real-time kit obtained from QuantaBio (Beverly, MA) as described before56,57. The following primer sequences were used:
iNOS: Sense: 5′-CCCTTCCGAAGTTTCTGGCAGCAGC-3′
IL-1β: Sense: 5′-GGA TATGGAGCAACAAGTGG-3′
GAPDH: Sense: 5′-GGTGAAGGTCGGTGTGAACG-3′
Animals were perfused with 4% paraformaldehyde, and the brains were kept in a 30% sucrose solution at 4 °C. Using a cryotome, 30-μm coronal sections were cut from the midbrain region of the brain and processed for immunostaining. In the case of cell samples (primary microglia), these were washed with PBS and then fixed with 4% paraformaldehyde followed by immunostaining. Samples were blocked with either 4% (for tissue sections) or 2% (for cells) BSA in PBS containing 0.5% Tween-20 (Sigma) and 0.05% Triton X-100 (Sigma) for 1 h. Then the samples were kept in primary antibodies for α-syn (1:500, MJFR1, Abcam), psyn129 (1:2000, Abcam), TH (1:1000, Pel-Freeze and Jackson Immunostar), Iba1 (1:1000, Abcam), GFAP (1:2000, Abcam), iNOS (1:200, BD Bioscience) and incubated at 4 °C temperature overnight under shaking conditions. The next day, the samples were washed with PBS for 30 min and further incubated with Cy2- or Cy5-labeled secondary antibodies (all 1:500; Jackson Immuno-Research) for 2 h under similar shaking conditions. Following four 15-min washes with PBS, cells were incubated for 4–5 min with 4′,6-diamidino-2-phenylindole (DAPI, 1:10,000; Sigma). For immunohistochemistry of brain sections, samples were kept in a solution containing biotin-tagged secondary antibodies for 2 h followed by incubation in Vectastain A and B mixture solution at RT. Sections were developed by 3,3′-diaminodenzidine (DAB) solution containing peroxide. The sections were mounted on coated slides, dried overnight, and were run in an ethanol and xylene (Fisher) gradient and observed under either Olympus BX41 fluorescence microscope or imaged under Zeiss confocal microscope using Zen 2012 software (Zeiss LSM 780, Carl Zeiss, Jena, Germany). Mean fluorescence intensity (MFI) and counting of target proteins or cells were performed using ImageJ. Intensity of pSyn129 DAB staining was quantified using Fiji (ImageJ2). All figures were deconvoluted to achieve H-DAB stained images and then each cell was outlined and the intensity was measured by the Analyze-measure option provided in the software. The mean value of stained cells in A53T brains (including PBS and PFF-injected) was compared to that of cells of nTg brain. Darker staining means lower is the mean value. The mean value of white is considered to be the highest (255), and therefore the formula used for calculating relative O.D. is log10(255/mean of each cell).
Mouse stereotaxic surgery
It was performed according to the procedure mentioned by Sorrentino and co-workers18. The A53T animals start showing significantly visible α-syn pathology at 4–6 months of stage20. Therefore, α-syn PFF was injected into the internal capsule (IC) region of striatum of 3-months-old A53T mice, so that the seeded α-syn fibrils spread up to SN of the midbrain overtime. Animals were injected with 5 µg of α-syn fibrils dissolved in 2.5 µl of PBS in the internal capsule region in both the hemispheres of the brain (coordinates from Bregma: A/P −0.5, L ±1.5, D/V −3.0). Similarly, control animals were injected with only PBS in both the hemispheres. The solution was injected at the rate of 0.4 µl/min and following the injection, the needle was kept for another 5 min on each side of the brain for proper diffusion of the protein solution18.
Intranasal treatment of animals with TIDM and NBD peptides
Wild type (wt) TIDM, mutated (m) TIDM, and wtNBD peptides were solubilized in normal saline in such a way so that each mouse receives 0.1 mg/kg of body weight TIDM/NBD peptide in 2.5 µl of saline. Then 2.5 µl of TIDM/NBD solution was administered in mice through each nostril every day for a total of 30 days. Mice were held in supine condition while administering TIDM/NBD solutions14. Intranasal treatment was started for PFF or PBS-injected A53T animals at the age of 5 months (2 months following the brain surgery) for the next 30 days. Aged A53T animals (8 months old) were also treated with TIDM/NBD peptides for 1 month followed by behavioral tests and other experiments at the age of 9 months.
For evaluating the bioavailability of TIDM peptides in mice brain, A53T mice were treated with Alexa-680 tagged wtTIDM or mTIDM through the tail vein. Similarly, control mice were treated with only Alexa-680, which was not tagged with the peptide. Following 2 h of dye injection, animals were scanned under LICOR infrared scanner to visualize the penetration of the peptides in the brain as described before44. Lastly, the experimental animals were sacrificed and different blocks of the brain were taken from the cortex, midbrain, and cerebellum region and further scanned under the LICOR scanner.
Two major kinds of behavioral tests (open field and rotarod) were conducted to evaluate PFF α-syn-induced motor deficits in mice.
Open field: Open field test was conducted to look at the locomotor activities of the animals. Locomotor activity was monitored with a camera linked to Noldus system and EthoVisionXT software (Netherlands). The instrument records the overall movement abilities of the animals including total distance moved, velocity, total moving time, resting time, center time, and frequencies of movement and rest. Before the test, mice were placed inside the open field arena for 10 min daily for two consecutive days to train them and record their baseline values. Two days after the training, each mouse was taken from the cage and gently placed in the middle of the open field arena. After releasing the animal, data acquisition was started by the software for the next 5 min and the parameters related to the locomotor activities were collected by the software58.
Rotarod: Prior to the rotarod test, mice were placed on the rotarod instrument for 5–10 min daily for consecutive two days to train them. After 2 days of training, mice were placed on the rotating rod, which rotates with a gradual increasing speed of 4–40 rpm. The experiment was ended if the animals slips from the rotating rod to the base of the instrument or just grips the rod to turn reverse without rotating against the direction of rotating rod16.
Pole test: It was performed with a wooden pole of 57 cm in height and 2 cm in width. Animals were acclimatized for two consecutive days prior to the test and each time five trials were given to each animal. During the test, animal was placed near the top of the pole facing upwards. The time taken by each animal to turn downwards was monitored as the pole turn time. Moreover, the time taken by each animal to reach the base of the pole was recorded as the pole climb downtime. The surface of the pole was made rough by covering it with bandage gauze. The maximum time for recording was set as 60 s. If any animal was found to stall for more than 60 s, the test was further performed for that particular animal16,59.
Tissue lysate preparation
Midbrain tissues were isolated from experimental mice and homogenized in Triton X-100 soluble buffer containing 1% Triton X-100, 0.5 µM EDTA, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl and protease inhibitors, and phosphatase inhibitor cocktails. The homogenate was centrifuged at 17,500 × g for 15 min at 4 °C. The supernatant obtained after centrifugation was the detergent soluble fraction of the tissue. The resultant pellet was dissolved in detergent-insoluble buffer containing 50 mM Tris, pH 8.0, 1% Triton X-100, 2% SDS, 1% sodium-deoxycholate, 1% NP-40, 0.5 µM EDTA and protease, phosphatase inhibitor cocktails. The lysate was further centrifuged at 17,500 × g for 15 min at 4 °C and the supernatant was collected as the Triton X-100 insoluble fraction16,43. Total tissue lysate was obtained by dissolving the tissue in RIPA buffer (50 mM Tris, pH 8.0,150 mM NaCl, 1% Nonidet P-40, 1% SDS, 0.5% sodium-deoxycholate) with complete protease and phosphatase inhibitor cocktails. Tissues were sonicated for 20–30 s and the homogenate was centrifuged at 17,500 × g for 15 min at 4 °C and the resulting supernatant was collected50.
TH neuronal counting
TH immunohistochemistry in both SN and striatum was performed according to the protocol mentioned earlier58,60. Counting of TH neurons in SN of each hemisphere of the brain was performed by using STEREO INVESTIGATOR software (MicroBrightfield, Williston, VT) having an optical fractionator as described before21,60. TH fiber density in the striatum was measured by using the Fiji software.
HPLC analysis for measurement of striatal DA and its metabolite levels
Striatal levels of DA, DOPAC, and HVA were measured as mentioned earlier58. In brief, after 7 days of MPTP treatment, mice were sacrificed by cervical dislocation, and striatum was isolated from each mouse and sonicated in 0.2 M ice-cold perchloric acid. The homogenate was centrifuged at 17,500 × g for 15 min at 4 °C. Supernatant was collected in a fresh tube and 10 µl of the supernatant was injected in an Eicompak SC-3ODS column (Complete Stand-Alone HPLC-ECD System EiCOMHTEC-500; JM Science, Grand Island, NY). Levels of neurotransmitters were analyzed according to the manufacturer’s protocol.
Statistics were performed using GraphPad Prism v7.0. Values are expressed as mean ± S.D. for data obtained from cellular studies and mean ± S.E. for animal experiments. At least three experiments were conducted for each analysis. Statistical analyses for differences between two different samples were performed using an unpaired two-tailed t-test. One-way ANOVA followed by Tukey’s multiple comparisons was performed for statistical analyses among multiple groups. Two-way ANOVA was used for comparing more than one parameter among different groups. The criterion for statistical significance was p < 0.05.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All data supporting the findings of this study are provided within the paper and its Supplementary Information. A source data file is provided with this paper. All additional information will be made available upon reasonable request to the authors. Source data are provided with this paper.
Feigin, V. L. et al. Global, regional and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459–480 (2019).
Betarbet, R., Sherer, T. B., Di Monte, D. A. & Greenamyre, J. T. Mechanistic approaches to Parkinson’s disease pathogenesis. Brain Pathol. 12, 499–510 (2002).
Bayer, T. A. et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease beta-amyloid plaque cores. Neurosci. Lett. 266, 213–216 (1999).
Taguchi, K., Watanabe, Y., Tsujimura, A. & Tanaka, M. Brain region-dependent differential expression of alpha-synuclein. J. Comp. Neurol. 524, 1236–1258 (2016).
Hofer, A. et al. The role of alpha-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies. J. Neural Transm. 112, 1249–1254 (2005).
Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular alpha–synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98 (2014).
Kim, C. et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).
Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009).
Rostami, J. et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J. Neurosci. 37, 11835–11853 (2017).
Lee, H. J., Kim, C. & Lee, S. J. Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection. Oxid. Med. Cell Longev. 3, 283–287 (2010).
Lee, E. J. et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185, 615–623 (2010).
Beutler, B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257–263 (2004).
O’Neill, L. A., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 13, 453–460 (2013).
Rangasamy, S. B. et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer’s pathology. J. Clin. Invest. 128, 4297–4312 (2018).
Kim, C. et al. Antagonizing neuronal toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Rep. 13, 771–782 (2015).
Yun, S. P. et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat. Med. 24, 931–938 (2018).
Mao, X. et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).
Sorrentino, Z. A. et al. Intrastriatal injection of alpha-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol. Neurodegener. 12, 40 (2017).
Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
Lee, M. K. et al. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53–> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968–8973 (2002).
Ghosh, A. et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 104, 18754–18759 (2007).
May, M. J. et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289, 1550–1554 (2000).
Khanlou, N. et al. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J. Neurovirol 15, 131–138 (2009).
Kuhbandner, K. et al. alpha-Synuclein: a modulator during inflammatory CNS demyelination. J. Mol. Neurosci. 70, 1038–1049 (2020).
Rangasamy, S. B. et al. Intranasal delivery of NEMO-binding domain peptide prevents memory loss in a mouse model of Alzheimer’s disease. J. Alzheimers Dis. 47, 385–402 (2015).
Bae, E. J. et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat. Commun. 5, 4755 (2014).
Barkholt, P., Sanchez-Guajardo, V., Kirik, D. & Romero-Ramos, M. Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 208, 85–96 (2012).
Stoica, G. et al. Potential role of alpha-synuclein in neurodegeneration: studies in a rat animal model. J. Neurochem. 122, 812–822 (2012).
Klucken, J. et al. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8, 754–766 (2012).
Stefanis, L. et al. How is alpha-synuclein cleared from the cell? J. Neurochem. 150, 577–590 (2019).
Emmanouilidou, E. & Vekrellis, K. Exocytosis and spreading of normal and aberrant alpha-synuclein. Brain Pathol. 26, 398–403 (2016).
Gustafsson, G. et al. Secretion and uptake of alpha-synuclein via extracellular vesicles in cultured cells. Cell Mol. Neurobiol. 38, 1539–1550 (2018).
Cheng, J., Lu, Q., Song, L. & Ho, M. S. alpha-Synuclein trafficking in Parkinson’s disease: insights from fly and mouse models. ASN Neuro. 10, 1759091418812587 (2018).
Gordon, R. et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 10, eaah4066 (2018).
Lee, H. J. et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262–9272 (2010).
Izco, M., Blesa, J., Verona, G., Cooper, J. M. & Alvarez-Erviti, L. Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson’s disease. Neurosci. Res. 170, 330–340 (2020).
Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 133, 303–319 (2017).
Kim, C., Lee, H. J., Masliah, E. & Lee, S. J. Non-cell-autonomous neurotoxicity of alpha-synuclein through microglial toll-like receptor 2. Exp. Neurobiol. 25, 113–119 (2016).
Kim, C. et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol. Neurodegener. 13, 43 (2018).
Russ, K. et al. TNF-alpha and alpha-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. Cell Rep. 34, 108895 (2021).
Johnson, H. M., Ahmed, C. M. & Noncanonical, I. F. N. Signaling: mechanistic linkage of genetic and epigenetic events. Mediators Inflamm. 2016, 9564814 (2016).
Jana, M., Anderson, J. A., Saha, R. N., Liu, X. & Pahan, K. Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes. Free Radic. Biol. Med. 38, 655–664 (2005).
Karampetsou, M. et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Sci. Rep. 7, 16533 (2017).
Rangasamy, S. B. et al. Selective disruption of TLR2/MyD88 interaction inhibits inflammation and attenuates Alzheimer’s pathology. J. Clin. Invest. 128, 4297–4312 (2018).
Mondal, S. et al. Testing NF-kappaB-based therapy in hemiparkinsonian monkeys. J. Neuroimmune Pharm. 7, 544–556 (2012).
Jana, M., Jana, A., Pal, U. & Pahan, K. A simplified method for isolating highly purified neurons, oligodendrocytes, astrocytes, and microglia from the same human fetal brain tissue. Neurochem. Res. 32, 2015–2022 (2007).
Jana, M., Palencia, C. A. & Pahan, K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer’s disease. J. Immunol. 181, 7254–7262 (2008).
Chandra, G. et al. Increase in mitochondrial biogenesis in neuronal cells by RNS60, a physically-modified saline, via phosphatidylinositol 3-kinase-mediated upregulation of PGC1alpha. J. Neuroimmune Pharm. 13, 143–162 (2018).
Gottschalk, C. G., Roy, A., Jana, M., Kundu, M. & Pahan, K. Activation of peroxisome proliferator-activated receptor-alpha increases the expression of nuclear receptor related 1 protein (Nurr1) in dopaminergic neurons. Mol. Neurobiol. 56, 7872–7887 (2019).
Dutta, D. et al. Low levels of prohibitin in substantia nigra makes dopaminergic neurons vulnerable in Parkinson’s disease. Mol. Neurobiol. 55, 804–821 (2018).
Roy, A. et al. Identification and characterization of PPARalpha ligands in the hippocampus. Nat. Chem. Biol. 12, 1075–1083 (2016).
Ghosh, A. et al. Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J. Biol. Chem. 290, 10309–10324 (2015).
Jana, M., Dasgupta, S., Saha, R. N., Liu, X. & Pahan, K. Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J. Neurochem. 86, 519–528 (2003).
Khasnavis, S. et al. Suppression of nuclear factor-kappaB activation and inflammation in microglia by physically modified saline. J. Biol. Chem. 287, 29529–29542 (2012).
Paidi, R. K. et al. ACE-2-interacting domain of SARS-CoV-2 (AIDS) peptide suppresses inflammation to reduce fever and protect lungs and heart in mice: implications for COVID-19 Therapy. J. Neuroimmune Pharm. 16, 59–70 (2021).
Patel, D. et al. Aspirin binds to PPARalpha to stimulate hippocampal plasticity and protect memory. Proc. Natl Acad. Sci. USA 115, E7408–E7417 (2018).
Rangasamy, S. B., Dasarathi, S., Pahan, P., Jana, M. & Pahan, K. Low-dose aspirin upregulates tyrosine hydroxylase and increases dopamine production in dopaminergic neurons: implications for Parkinson’s disease. J. Neuroimmune Pharm. 14, 173–187 (2019).
Chandra, G., Roy, A., Rangasamy, S. B. & Pahan, K. Induction of adaptive immunity leads to nigrostriatal disease progression in MPTP mouse model of Parkinson’s disease. J. Immunol. 198, 4312–4326 (2017).
Matsuura, K., Kabuto, H., Makino, H. & Ogawa, N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73, 45–48 (1997).
Ghosh, A. et al. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson’s disease. J. Neurosci. 29, 13543–13556 (2009).
This study was supported by grants from the National Institutes of Health (NS108025 and AG069229). Moreover, Dr. Pahan is the recipient of a Research Career Scientist Award (1IK6 BX004982) from the Department of Veterans Affairs.
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dutta, D., Jana, M., Majumder, M. et al. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nat Commun 12, 5382 (2021). https://doi.org/10.1038/s41467-021-25767-1
This article is cited by
α-Synuclein induces prodromal symptoms of Parkinson’s disease via activating TLR2/MyD88/NF-κB pathway in Schwann cells of vagus nerve in a rat model
Journal of Neuroinflammation (2023)
A STIR nucleic acid drug delivery system for stirring phenotypic switch of microglia in Parkinson’s disease treatments
Nano Research (2023)
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Neuroscience Bulletin (2023)
Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson’s disease
Inflammation Research (2023)
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Current Neurology and Neuroscience Reports (2022)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.